A to Z / Metabolic / weight loss

Compounded GLP-1 Products

Also known as compounded semaglutide, compounded tirzepatide, grey market GLP-1.

Best known for Compounded versions of the most sought-after weight-loss medicines

Evidence★★★☆☆

Safety dataPoorly characterised

Route injectable (subcutaneous)

United StatesCompounding restricted

AustraliaPharmacist compounding prohibited

as at 16 September 2026

What it is

Compounded GLP-1 products are versions of semaglutide or tirzepatide made by compounding pharmacies rather than the original manufacturer. They became widespread during the global shortage, when regulators permitted compounding to fill a gap that branded supply could not.

This entry is about the product, not the molecule. Semaglutide and tirzepatide have their own entries and excellent evidence. The open question here is whether what's in the vial matches what's on the label.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Semaglutide, Tirzepatide, Retatrutide

Related entries

SemaglutideThe drug that changed obesity treatment · Evidence ★★★★★
TirzepatideThe most effective approved weight-loss drug · Evidence ★★★★★
RetatrutideThe next-generation weight-loss drug that isn't approved yet · Evidence ★★☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Compounded GLP-1 Products. It is not medical advice and not a recommendation to use it.